PPT-Crysvita ® ( burosumab-twza

Author : eleanor | Published Date : 2024-03-13

A Summary of Clinical Trial Data MRCPKRN2300318 518 Crysvita Overview Indications and Usage Crysvita is a fibroblast growth factor 23 FGF23 blocking antibody

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Crysvita ® ( burosumab-twza" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Crysvita ® ( burosumab-twza: Transcript

A Summary of Clinical Trial Data MRCPKRN2300318 518 Crysvita Overview Indications and Usage Crysvita is a fibroblast growth factor 23 FGF23 blocking antibody indicated for the treatment of Xlinked hypophosphatemia XLH in adult . Nick Shaw. Consultant Paediatric Endocrinologist. Birmingham Children’s Hospital. . Personal Experience. Invitation from NICE to act as a clinical expert on the HTA evaluation for:. Asfotase. Alfa for .

Download Document

Here is the link to download the presentation.
"Crysvita ® ( burosumab-twza"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.